Baricitinib + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus
Trial Timeline
Aug 2, 2018 → Oct 20, 2021
NCT ID
NCT03616964About Baricitinib + Placebo
Baricitinib + Placebo is a phase 3 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is completed. This product is registered under clinical trial identifier NCT03616964. Target conditions include Systemic Lupus Erythematosus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07222332 | Phase 3 | Recruiting |
| NCT07222137 | Phase 3 | Recruiting |
| NCT05237388 | Phase 2 | Recruiting |
| NCT05723198 | Phase 3 | Recruiting |
| NCT04421027 | Phase 3 | Completed |
| NCT03843125 | Phase 3 | Terminated |
| NCT03899259 | Phase 3 | Completed |
| NCT03742973 | Phase 2 | Terminated |
| NCT03773978 | Phase 3 | Completed |
| NCT03570749 | Phase 2/3 | Completed |
| NCT03616964 | Phase 3 | Completed |
| NCT03616912 | Phase 3 | Terminated |
| NCT03334435 | Phase 3 | Completed |
| NCT03435081 | Phase 3 | Completed |
| NCT03334422 | Phase 3 | Completed |
| NCT03334396 | Phase 3 | Completed |
| NCT02758613 | Phase 1 | Completed |
| NCT02708095 | Phase 2 | Completed |
| NCT02265705 | Phase 3 | Completed |
| NCT01885078 | Phase 3 | Completed |
Competing Products
20 competing products in Systemic Lupus Erythematosus